PCSK9 and atherosclerosis: Canadian guidelines recommend statins for all patients with established ASCVD, additionally, ezetimibe and PCSK9 inhibitors are recommended to lower LDL‐C,28 and decrease the risk of subsequent CV events in ASCVD patients above the LDL‐C threshold of 1.8 mmol/L.18, 29, 30, 31